INS and Hypoglycemia: Increasing evidence suggests these medicines have lower risk of hypoglycaemia than sulphonylureas and insulin, promote weight loss or are weight neutral [1], and reduce cardiovascular outcomes [15] and mortality in patients at increased cardiovascular risk [16].